China Pharma approved to market three injectable generics for cardiovascular disease

By Lisa Kerner

Charlotte, N.C., June 19 - China Pharma Holdings said it received approvals from China's State Food and Drug Administration to manufacture and market three new prescription-only, injectable generic products: Ozagrel, Propylgallate and Alginic Sodium Diester.

Ozagrel is a selective thromboxane A2 (TXA2) synthase inhibitor for the treatment of acute embolic stroke.

As a prophylaxis and treatment, Propylgallate is indicated for coronary heart disease, cerebral embolism and thrombophlebitis after surgery.

Alginic Sodium Diester is a semi-synthetic drug for use in patients with ischemic cardiovascular and cerebrovascular diseases, as well as high lipid levels.

Cardiovascular and cerebrovascular diseases have become top threats to public health in China, according to a company news release.

Located in Haikou City, Hainan Province, China Pharma is a U.S. public company. Its subsidiary, Helpson Bio-pharmaceutical Co. Ltd., develops, manufactures and markets generic and brand pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.